The Patients' Perspective of Important Glucocorticoid Effects: A Nominal Group Study Among Patients With Systemic Lupus Erythematosus and Myositis. Issue 6 (September 2021)

• Record Type: Journal Article
• Authors: Mirza, Serene Z.; Cheah, Jonathan T. L.; Ghosh, Nilasha; Robson, Joanna C.; Hill, Catherine L.; Singh, Jasvinder; Mackie, Sarah L.; Navarro-Millán, Iris; Simon, Lee S.; Goodman, Susan M.
• Is Part Of: Journal of clinical rheumatology. Volume 27:Issue 6(2021)
• Publication Date: 2021-09
• Subjects: glucocorticoids -- myositis -- nominal group -- patient perspective -- systemic lupus erythematosus; Rheumatism -- Periodicals; Rheumatology -- Periodicals; Musculoskeletal system -- Diseases -- Periodicals; Musculoskeletal Diseases -- Periodicals; Rheumatic Diseases -- Periodicals; Rhumatisme -- Périodiques; Rhumatologie -- Périodiques; Appareil locomoteur -- Maladies -- Périodiques; Musculoskeletal system -- Diseases; Rheumatism; Rheumatology; Periodicals; 616.723005
• DOI: 10.1097/RHU.0000000000001313
• Languages: English
• ISSNs: 1076-1608

Abstract

Abstract : Background/Objective: The objective of this cohort study was to understand the positive and negative effects of glucocorticoids (GCs) in patients with systemic lupus erythematosus and myositis from the patients' perspective with the aim of developing a patient-reported outcome measure. Methods: Included patients were asked to participate in 1 of 5 nominal groups where demographic information and a quality-of-life questionnaire were collected. Patients were asked 2 open-ended questions on (1) benefits and (2) harms related to GC use. We used the Nominal Group Technique, a highly structured consensus method in which responses are generated, shared, and ranked. Descriptive statistics were used to summarize the results. Nominal group sessions took place from April to May 2019. Results: Of 206 patients who were approached, 21 patients participated, 17 with systemic lupus erythematosus and 4 with myositis, predominantly women with more than 10 years of steroid use. The domains ranked highest for GC benefits were disease control (55 votes), fast onset of action (30 votes), increased energy (10 votes), and pain relief (10 votes). The highest-ranked negative effects were bone loss (38 votes) and weight gain (16 votes); psychological effects and damaged internal organs each received 12 votes. Conclusions: The top-ranked GC effects—both benefits and harms—among patients with systemic rheumatic disease are consistent with the top domains associated with GC use reported with other inflammatory diseases. This study informs the development of a comprehensive patient-reported outcome measure that can be used across inflammatory diseases. Abstract : Supplemental digital content is available in the text.